KellyB.PendergrassMD
Oncology • Blue Springs, MOAssistant Professor, Internal Medicine, University Kansas School of Medicine
Dr. Pendergrass is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
4881 NE Goodview Cir
Blue Springs, MO 64064Phone+1 913-574-2350Fax+1 913-574-2413
Education & Training
University of TennesseeResidency, Internal Medicine, 1975 - 1978
University of Kansas School of MedicineClass of 1975
Certifications & Licensure
KS State Medical License 1994 - 2025
LA State Medical License 2021 - 2022
MO State Medical License 1980 - 2021
MD State Medical License 1979 - 1983
Awards, Honors, & Recognition
- Super Doctor SuperDoctors.com
- Top MD Consumers Checkbook
Clinical Trials
- Carboplatin With Either Paclitaxel Poliglumex or Paclitaxel in Treating Women With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer Start of enrollment: 2007 Aug 01
- Myelodysplastic Syndromes (MDS) Event Free Survival With Iron Chelation Therapy Study Start of enrollment: 2010 Mar 22
- Study of 0.1% Uracil Topical Cream (UTC) for the Prevention of Hand-Foot Syndrome Start of enrollment: 2010 Apr 01
- Join now to see all
Publications & Presentations
PubMed
- 10 citationsFirst-line vs second-line fulvestrant for hormone receptor-positive advanced breast cancer: A post-hoc analysis of the CONFIRM studyAngelo Di Leo, Guy Jerusalem, Roberto Torres, Didier Verhoeven, Kelly Pendergrass
Breast. 2018-04-01 - 18 citationsTITAN: phase III study of doxorubicin/cyclophosphamide followed by ixabepilone or paclitaxel in early-stage triple-negative breast cancerDenise A. Yardley, Edward Arrowsmith, Brooke R. Daniel, Janice F. Eakle, Adam Brufsky
Breast Cancer Research and Treatment. 2017-05-15 - 108 citationsA randomized trial of avatrombopag, an investigational thrombopoietin-receptor agonist, in persistent and chronic immune thrombocytopeniaJames B. Bussel, David J. Kuter, Louis M. Aledort, Craig M. Kessler, Adam Cuker
Blood. 2014-06-19
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
